Beam Therapeutics (BEAM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Beam stock launched a year-high Tuesday as enthusiasm grows for its next-generation form of gene editing, a rival to CRISPR.
Beam Therapeutics stock saw a welcome improvement to its Relative Strength (RS) Rating on Tuesday, with an upgrade from 73 to 81. The Cambridge, Mass.-biotech company reported strong Q4 and full year 2023 results and reiterated milestones across the company's sickle cell disease and genetic disease portfolios. Check out "Beam Rockets 27%, Hitting A Year High, On Its Efforts To Take On Crispr's New Gene-Editing Drug."